ITM Reports Re-treatment and Dosimetry Data for 177Lu-Edotreotide
BOSTON, Mass. — September 27, 2026 ITM Isotope Technologies Munich SE and Lumara Bio announced new real-world re-treatment and...
nuclear medicine
Advertisement
Telix and ITM Announce $1.65B Radiopharmaceutical Merger
Melbourne, Australia; Indianapolis, U.S.; Munich, Germany, September 21, 2026 Telix Pharmaceuticals Limited has announced a strategic agreement to lead...
Curium Gains FDA Approval for BEXLUTRY in GEP-NETs
BOSTON, Mass. — September 14, 2026 Curium™ announced that the U.S. Food and Drug Administration (FDA) has approved its...
GE HealthCare Advances StarGuide GX for Theranostics
CHICAGO — September 8, 2026 GE HealthCare announced that its new StarGuide GX digital 4D CZT SPECT/CT system is...
Telix Completes BiPASS Enrollment and Aligns With FDA
MELBOURNE, Australia and INDIANAPOLIS, September 2, 2026 Telix Pharmaceuticals Limited has completed enrollment of 350 patients in its Phase...
Advertisements
Curium to Merge with Lantheus in $8B Radiopharma Deal
Boston & Bedford, Massachusetts, August 3, 2026 Curium and Lantheus Holdings, Inc. have entered into a definitive merger agreement...
Novartis’ Pluvicto Wins FDA Approval for Earlier Prostate Cancer Treatment
SILVER SPRING, Md., July 31, 2026 The U.S. Food and Drug Administration (FDA) has approved Novartis’ Pluvicto (lutetium Lu...
Spectrum Dynamics Launches VERITON-CT 400 Enhancement
MORGES, Switzerland, July 20, 2026 Spectrum Dynamics Medical has announced the launch of the All-Energy Enhancement for its FDA-cleared,...
Telix Doses First Patient in Phase 3 LUTEON Trial of TLX250-Tx
MELBOURNE, Australia, and INDIANAPOLIS, Ind., July 21, 2026 Telix Pharmaceuticals announced that the first patient has been dosed in...
Telix Completes Phase 3 Enrollment for Illuccix in Japan
MELBOURNE, Australia, and TOKYO, Japan, July 17, 2026 Telix Pharmaceuticals has completed patient enrollment in its pivotal Phase 3...
Advertisement
